Septerna's SEP-631 demonstrates dose-dependent skin response in Phase 1 urticaria study, establishing mechanistic link to MRGPRX2 receptor occupancy in...

BioAge Labs advances BGE-102 NLRP3 inhibitor into Phase 2 cardiovascular trial after Phase 1 showed 86% median hsCRP reduction.

Actuate advances oral elraglusib into Phase 1/2 after FDA IND clearance, targeting superior systemic exposure versus IV formulation.

MoonLake's sonelokimab hidradenitis suppurativa treatment gains FDA clearance with the highest efficacy rates ever recorded in an adequate, well-controlled...

Intellia's lonvoguran ziclumeran reduced HAE attacks 87% in Phase 3, with 62% of patients remaining attack-free for six months...

FDA approves efgartigimod for all adult generalized myasthenia gravis types, including seronegative patients previously excluded from treatment labels.

Cardior's CDR132L cleared safety hurdles in phase 2 but missed primary cardiac structure endpoints—a rigorous negative result that reshapes...

A Vanguard Publications Q&A with Madelyn, Neuro-Innovators.

CytomX closes dose optimization for varsetatug masetecan with 2H 2026 data readout expected to determine monotherapy selection and registrational...

Denali pursues DNL593 alone in GRN-FTD after Takeda's exit, with Phase 1/2 data expected before year-end in this genetically...